12 news items
Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic
COYA
20 Jun 24
of COYA 301 (LD IL-2) with other relevant drug products, following the innovative approach of COYA 302 (LD IL-2 + CTLA4-Ig) targeting multiple paths
Rodman & Renshaw Initiates Coverage On Coya Therapeutics with Buy Rating, Announces Price Target of $18
COYA
13 Jun 24
Rodman & Renshaw analyst Elemer Piros initiates coverage on Coya Therapeutics (NASDAQ:COYA) with a Buy rating and announces Price Target of $18.
Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology
COYA
11 Jun 24
of regulatory T cells ("Tregs") to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including
Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology
COYA
3 Jun 24
developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells ("Tregs") to target systemic
Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index
COYA
28 May 24
") to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic
lvmaeccffycj57d50522j gyduvmoanbq
BIIB
COYA
27 May 24
biotechnology company developing treatments focused on regulatory T cells (Tregs) to target systemic inflammation and neuroinflammation
gvnvek2
COYA
22 May 24
of regulatory T cells ("Tregs") to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including
1v2j6kgrlzc oj3acmsvlz4hyxptg
COYA
20 May 24
302, is an innovative approach being developed to suppress neuroinflammation by targeting multiple inflammatory pathways," said Howard Fillit, M.D
s1hjelam0vfibvul8ccmat0327l9sbtpv5l07br0hl5suwr0yq6ngipm186q
COYA
9 May 24
proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells ("Tregs") to target systemic inflammation
dlj7spwf2azsshulagffhgkoybmn2fd2kvso3kcy8n4jh348aeli5mvgj
COYA
26 Apr 24
of regulatory T cells ("Tregs") to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including
r80nxh5xlu4t6wlnnzqz59wuxvabpfga5
COYA
18 Apr 24
") to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic
njdt07h8wku7549yhp25uw0svqitszb bwid6xds2a
COYA
8 Apr 24
") to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic
- Prev
- 1
- Next